Single-Dose PCSK9 Base Editing Achieves Durable LDL Reduction : NEJM | May 2026

Introduction

Hypercholesterolemia remains a major driver of atherosclerotic cardiovascular disease despite the availability of statins, PCSK9 inhibitors and RNA-based therapies. Lifelong treatment adherence and incomplete LDL reduction continue to limit long-term risk modification in high-risk populations.

Problem Statement

Whether in vivo gene editing can safely achieve durable suppression of PCSK9 and sustained LDL cholesterol reduction after a single treatment remains a major unanswered question in cardiovascular therapeutics.

Summary

This first-in-human phase 1 study evaluated VERVE-102, an investigational liver-directed base-editing therapy designed to permanently inactivate PCSK9 following a single intravenous infusion.

VERVE-102 uses a lipid nanoparticle platform delivering messenger RNA encoding an adenine base editor together with guide RNA targeting PCSK9. The therapeutic strategy is based on naturally occurring loss-of-function PCSK9 variants associated with lifelong low LDL cholesterol levels and reduced cardiovascular risk.

The study demonstrated clear dose-dependent reductions in circulating PCSK9 and LDL cholesterol levels across escalating dose cohorts. At the highest dose level, LDL cholesterol fell by more than 60%, with substantial absolute LDL reductions sustained throughout follow-up.

Importantly, lipid lowering appeared durable over time, with maintained reductions extending beyond one year in available participants. These findings strongly support the feasibility of permanent in vivo gene editing as a potentially transformative “one-and-done” lipid-lowering strategy.

Safety outcomes were encouraging in this early-phase trial. No dose-limiting toxicities were observed, and most adverse events consisted of mild infusion-related reactions or transient liver enzyme elevations. No major safety signal directly related to gene editing emerged during follow-up.

The study represents a major milestone in clinical base-editing therapeutics. Unlike CRISPR nuclease-based approaches that create double-stranded DNA breaks, adenine base editing introduces targeted nucleotide changes without generating double-strand cleavage, theoretically reducing genomic instability risks.

Clinically, the implications are substantial. Patients with familial hypercholesterolemia or premature coronary artery disease often require lifelong multidrug lipid-lowering therapy, and treatment adherence remains a persistent challenge. Durable single-dose gene editing could fundamentally alter preventive cardiology.

The work also reflects the rapid convergence of lipid biology, RNA therapeutics and precision genome engineering. Following the success of siRNA therapies targeting PCSK9, permanent genomic suppression now appears technically achievable in humans.

Importantly, the study focused on patients at particularly high cardiovascular risk, including those with heterozygous familial hypercholesterolemia. These populations may derive the greatest benefit from sustained LDL reduction over decades.

The findings additionally raise broader questions regarding future management paradigms for chronic cardiometabolic disease. Gene editing may eventually transition cardiovascular prevention from chronic pharmacotherapy toward definitive molecular intervention.

Nevertheless, several critical uncertainties remain. Long-term durability, rare off-target editing effects, immunogenicity and very late safety outcomes require extended observation before broader implementation can be considered.

Cost, accessibility and ethical considerations surrounding permanent somatic gene editing will also become increasingly important as these technologies move toward larger clinical trials and potential commercialization.

The study additionally reinforces the growing therapeutic relevance of hepatocyte-directed gene editing platforms, which may eventually expand beyond lipid disorders into multiple inherited and metabolic liver diseases.

Overall, this phase 1 trial demonstrates that single-dose in vivo PCSK9 base editing with VERVE-102 can produce substantial, durable LDL cholesterol reduction with an encouraging early safety profile, marking a major advance toward permanent gene-editing therapies for cardiovascular disease prevention.